Why the study?
Does dimethyl sulphoxide (DMSO) inhibit human platelet aggregation in-vitro?
Does dimethyl sulphoxide (DMSO) inhibit human platelet aggregation in-vitro?
DMSO intrinsically inhibits human platelet aggregation in-vitro, highlighting the need to account for its effects when used as a solvent in pharmacological studies.
DMSO solvent effects require controls in platelet assays; leaves open in vivo or clinical relevance.
The effects were examined of the universal solvent dimethyl sulphoxide (DMSO) on human platelet aggregatory activity, in-vitro, of the endogenous mediators ADP, adrenaline, arachidonic acid, collagen and PAF-acether which are believed to play important roles in cardiovascular diseases in man. DMSO inhibited aggregation induced by all of the mediators in the order ADP greater than adrenaline = arachidonic acid = PAF-acether greater than collagen. Since DMSO is widely used as a solvent for drug substances, an awareness of its intrinsic activity in any such evaluations is essential.
No takes yet. Share an insight, caveat, or question.
Lehuu et al. (1987) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: